Ethinylestradiol/drospirenone

Drug Profile

Ethinylestradiol/drospirenone

Alternative Names: Dihydrospirorenone/ethinylestradiol; Drospirenone/ethinylestradiol; Petibelle; SH 470; Yasmin; ZK 30595

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy
  • No development reported Acne; Premenstrual dysphoric disorder; Premenstrual syndrome

Most Recent Events

  • 08 Sep 2015 Generic equivalent available in USA for Contraception
  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Switzerland, Norway, Israel, China, Malaysia, Philippines, Singapore, Thailand, Indonesia, Hong Kong and South Africa (PO) prior to February 2015
  • 11 Apr 2012 Bayer updated the labelling of ethinylestradiol/drospirenone regarding the risk of venous thromboembolism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top